查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613436

唐氏症市场：按产品、按疾病类型、按类型、按最终用户 - 全球预测 2025-2030

Down Syndrome Market by Offering (Assistive Devices, Medications), Disease Type (Mosaic Down Syndrome, Translocation, Trisomy 21), Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年唐氏症市值为18.9亿美元，预计到2024年将达到20.2亿美元，复合年增长率为7.44%，预计到2030年将达到31.2亿美元。

唐氏症是一种由额外 21 号染色体的存在引起的遗传性疾病，会影响认知和身体开拓，是医疗保健和健康领域各种市场机会的焦点。该领域的研究和应用需求源于治疗方法的缺乏，并正在推动市场开发治疗性介入、早期诊断工具以及教育和支持服务。最终用途范围从医疗保健提供者和家庭到热衷于加强支持基础设施和降低相关医疗保健成本的学术研究人员和政府机构。市场成长受到越来越多采用非侵入性产前检测（NIPT）、转向个人化医疗和遗传咨询服务的显着影响。此外，倡导早期疗育和综合护理的宣传活动显着提高了服务接受率。然而，挑战包括治疗和护理费用高昂、发展中地区缺乏认识以及产前筛检的伦理问题。开发先进辅助技术、行为治疗创新和行动医疗应用程式的机会很多，这些应用程式旨在帮助唐氏症患者及其家人进行日常管理和学习活动。此外，透过利用巨量资料分析和人工智慧，可以改善护理策略并预测健康结果。此外，诊断技术和有针对性的生物技术研究的创新为专业治疗的开发提供了一个有希望的途径。然而，参与企业必须克服监管障碍，并投资社区意识和教育，以提高护理品质。策略性地利用生物技术公司和医疗保健提供者之间的伙伴关係可以进一步推动市场成长，同时确保医疗保健的可及性和公平性。

主要市场统计
基准年[2023] 18.9亿美元
预计年份 [2024] 20.2亿美元
预测年份 [2030] 31.2亿美元
复合年增长率（%） 7.44%

市场动态：快速发展的唐氏症市场的关键市场洞察

供需的动态交互作用正在改变唐氏症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 唐氏症的盛行率和诊断率不断增加
    • 实施政府政策以支持取得唐氏症药物
    • 偏好治疗唐氏症的辅助技术
  • 市场限制因素
    • 先进治疗方法和诊断工具的高成本
  • 市场机会
    • 基因检测和筛检工具的技术进步
    • 政府资助唐氏症研究和意识提升计划
  • 市场挑战
    • 唐氏症的标准化有限且缺乏核准的适当治疗方法

波特的五力：驾驭唐氏症市场的策略工具

波特的五力架构是了解唐氏症市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解唐氏症市场的外部影响

外部宏观环境因素在塑造唐氏症市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解唐氏症市场的竞争格局

对唐氏症市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵唐氏症市场供应商绩效评估

FPNV定位矩阵是评估唐氏症市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘唐氏症市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对唐氏症市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 唐氏症的盛行率和诊断率不断增加
      • 实施政府政策支持获得唐氏症药物
      • 偏好治疗唐氏症的专门辅助技术
    • 抑制因素
      • 先进治疗方法和诊断工具的高成本
    • 机会
      • 基因检测和筛检工具的技术进步
      • 政府资助唐氏症研究并进行支持性意识计划
    • 任务
      • 唐氏症的标准化有限，并且没有适当的核准的治疗方法
  • 市场区隔分析
    • 产品：对辅助设备的需求可以满足随着患者年龄的增长而变化的各种需求
    • 最终使用者：为诊断、治疗和管理唐氏症提供广泛医疗服务的医院和诊所发挥重要作用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章唐氏症市场：副产品

  • 辅助器具
  • 药品

第七章唐氏症市场：依疾病类型

  • 马赛克唐氏症
  • 21三体

第 8 章唐氏症市场：依类型

  • 产后检查
  • 产前检测

第 9 章唐氏症市场：依最终用户分类

  • 居家照护环境
  • 医院/诊所
  • 治疗中心

第10章美洲唐氏症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区唐氏症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲唐氏症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Strand Life Sciences 宣布创新产前筛检技术
    • Yourgene Health 和 Laboriad 在摩洛哥推出非侵入性产前检测
    • FDA核准Inspire 疗法治疗患有严重 OSA 的青少年
  • 战略分析和建议

公司名单

  • AC Immune SA
  • Aelis Farma
  • Agilent Technologies, Inc.
  • Alzheon, Inc.
  • Annovis Bio
  • Aphios Corporation
  • Avanti Biosciences Inc. by Solid Biosciences Inc.
  • Bio-Rad Laboratories, Inc.
  • Demeditec Diagnostics GmbH
  • Elixirgen Therapeutics, Inc.
  • Illumina, Inc.
  • Inspire Medical Systems, Inc.
  • KinoPharma, Inc.
  • Laboratory Corporation of America Holdings
  • LifeCell International Private Limited by Allergan PLC
  • Lilac Insights Pvt. Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeuroNascent, Inc.
  • OPKO Health, Inc.
  • Pharmasum Therapeutics
  • Quest Diagnostics Incorporated
  • Roche Diagnostics Corporation
  • Strand Life Sciences by Reliance Industries Ltd.
  • Yourgene Health by Novacyt Group
Product Code: MRR-CB04E05659A9

The Down Syndrome Market was valued at USD 1.89 billion in 2023, expected to reach USD 2.02 billion in 2024, and is projected to grow at a CAGR of 7.44%, to USD 3.12 billion by 2030.

Down Syndrome, a genetic disorder caused by the presence of an extra chromosome 21, affects cognitive and physical development and is the focus of various market opportunities within the healthcare and wellness sectors. The necessity for research and application in this sphere is borne from the absence of a cure, which propels the market toward the development of therapeutic interventions, early diagnostic tools, and educational and support services. The end-use scope ranges from healthcare providers and families to academic researchers and governmental bodies, keen on enhancing support infrastructures and reducing the associated healthcare costs. Market growth is significantly influenced by the increasing adoption of non-invasive prenatal testing (NIPT) and a shift towards personalized medicine and genetic counseling services. Furthermore, awareness campaigns advocating early intervention and comprehensive care have significantly increased service adoption rates. However, challenges include high costs of treatment and care, lack of awareness in developing regions, and ethical concerns regarding prenatal screening. Opportunities abound in the development of advanced assistive technologies, behavioral therapy innovations, and mobile health applications designed to support those with Down Syndrome and their families in daily management and learning activities. The market may also leverage big data analytics and artificial intelligence to improve care strategies and predict health outcomes. Moreover, innovation in diagnostic technologies and targeted biotech research offers promising avenues for specialized treatment development. However, market players must navigate regulatory hurdles and invest in community education to enhance perception and quality of care. Strategically harnessing partnerships between biotech companies and healthcare providers can further propel market growth while ensuring access and equality in care, making it an attractive yet complex landscape for investment and development in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 1.89 billion
Estimated Year [2024] USD 2.02 billion
Forecast Year [2030] USD 3.12 billion
CAGR (%) 7.44%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Down Syndrome Market

The Down Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence and diagnosis rates of Down syndrome
    • Implementation of government policies to support access to Down syndrome medications
    • Preference for specialized assistive technologies to treat Down syndrome
  • Market Restraints
    • High cost of advanced therapies and diagnostic tools
  • Market Opportunities
    • Technological advancements in genetic testing and screening tools
    • Government funding for Down syndrome research with supportive awareness programs
  • Market Challenges
    • Limited standardization and unavailability of appropriate approved treatments for Down syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Down Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Down Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Down Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Down Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Down Syndrome Market

A detailed market share analysis in the Down Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Down Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Down Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Down Syndrome Market

A strategic analysis of the Down Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Down Syndrome Market, highlighting leading vendors and their innovative profiles. These include AC Immune SA, Aelis Farma, Agilent Technologies, Inc., Alzheon, Inc., Annovis Bio, Aphios Corporation, Avanti Biosciences Inc. by Solid Biosciences Inc., Bio-Rad Laboratories, Inc., Demeditec Diagnostics GmbH, Elixirgen Therapeutics, Inc., Illumina, Inc., Inspire Medical Systems, Inc., KinoPharma, Inc., Laboratory Corporation of America Holdings, LifeCell International Private Limited by Allergan PLC, Lilac Insights Pvt. Ltd., Myriad Genetics, Inc., Natera, Inc., NeuroNascent, Inc., OPKO Health, Inc., Pharmasum Therapeutics, Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Strand Life Sciences by Reliance Industries Ltd., and Yourgene Health by Novacyt Group.

Market Segmentation & Coverage

This research report categorizes the Down Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Assistive Devices and Medications.
  • Based on Disease Type, market is studied across Mosaic Down Syndrome, Translocation, and Trisomy 21.
  • Based on Type, market is studied across Postnatal Testing and Prenatal Testing.
  • Based on End-User, market is studied across Homecare Setting, Hospital & Clinics, and Therapy Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence and diagnosis rates of Down syndrome
      • 5.1.1.2. Implementation of government policies to support access to Down syndrome medications
      • 5.1.1.3. Preference for specialized assistive technologies to treat Down syndrome
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of advanced therapies and diagnostic tools
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in genetic testing and screening tools
      • 5.1.3.2. Government funding for Down syndrome research with supportive awareness programs
    • 5.1.4. Challenges
      • 5.1.4.1. Limited standardization and unavailability of appropriate approved treatments for Down syndrome
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Need for assistive devices to address a broad range of needs that can change as the patient ages
    • 5.2.2. End-User: Crucial role played by hospitals & clinics in providing a broad range of medical services for diagnosing, treating, and managing Down Syndrome
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Down Syndrome Market, by Offering

  • 6.1. Introduction
  • 6.2. Assistive Devices
  • 6.3. Medications

7. Down Syndrome Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Mosaic Down Syndrome
  • 7.3. Translocation
  • 7.4. Trisomy 21

8. Down Syndrome Market, by Type

  • 8.1. Introduction
  • 8.2. Postnatal Testing
  • 8.3. Prenatal Testing

9. Down Syndrome Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Setting
  • 9.3. Hospital & Clinics
  • 9.4. Therapy Centers

10. Americas Down Syndrome Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Down Syndrome Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Down Syndrome Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Innovative Prenatal Screening Technologies Launched by Strand Life Sciences
    • 13.3.2. Launch of Non-Invasive Prenatal Testing in Morocco by Yourgene Health and Laboriad
    • 13.3.3. FDA Approves Inspire Therapy for Teens with Down Syndrome and Severe OSA
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AC Immune SA
  • 2. Aelis Farma
  • 3. Agilent Technologies, Inc.
  • 4. Alzheon, Inc.
  • 5. Annovis Bio
  • 6. Aphios Corporation
  • 7. Avanti Biosciences Inc. by Solid Biosciences Inc.
  • 8. Bio-Rad Laboratories, Inc.
  • 9. Demeditec Diagnostics GmbH
  • 10. Elixirgen Therapeutics, Inc.
  • 11. Illumina, Inc.
  • 12. Inspire Medical Systems, Inc.
  • 13. KinoPharma, Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. LifeCell International Private Limited by Allergan PLC
  • 16. Lilac Insights Pvt. Ltd.
  • 17. Myriad Genetics, Inc.
  • 18. Natera, Inc.
  • 19. NeuroNascent, Inc.
  • 20. OPKO Health, Inc.
  • 21. Pharmasum Therapeutics
  • 22. Quest Diagnostics Incorporated
  • 23. Roche Diagnostics Corporation
  • 24. Strand Life Sciences by Reliance Industries Ltd.
  • 25. Yourgene Health by Novacyt Group

LIST OF FIGURES

  • FIGURE 1. DOWN SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. DOWN SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DOWN SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DOWN SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DOWN SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DOWN SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DOWN SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DOWN SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DOWN SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DOWN SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DOWN SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DOWN SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DOWN SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DOWN SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DOWN SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DOWN SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DOWN SYNDROME MARKET SIZE, BY ASSISTIVE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DOWN SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DOWN SYNDROME MARKET SIZE, BY MOSAIC DOWN SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DOWN SYNDROME MARKET SIZE, BY TRANSLOCATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DOWN SYNDROME MARKET SIZE, BY TRISOMY 21, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DOWN SYNDROME MARKET SIZE, BY POSTNATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DOWN SYNDROME MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DOWN SYNDROME MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DOWN SYNDROME MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DOWN SYNDROME MARKET SIZE, BY THERAPY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DOWN SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. DOWN SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. DOWN SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023